ArticleJournal of the National Cancer Institute2025
Human papillomavirus-related squamous cell carcinomas after blood or marrow transplantation-a Blood or Marrow Transplant Survivor Study report.
Article in Journal of the National Cancer Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanocarrier drug delivery systems for gynecological cancer therapeutics.Journal of controlled release : official journal of the Controlled Release Society · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundHuman papillomavirus (HPV) is associated with an increased risk for a variety of squamous cell carcinomas in the general population. The risk for subsequent squamous cell carcinomas in blood or marrow transplantation survivors that are potentially related to HPV (cervical, oropharyngeal, vulvar, vaginal, anal, and penile cancer; HPV-related squamous cell carcinomas) remains unknown.
methodsWe determined the risk of HPV-related squamous cell carcinomas in 7936 2-year survivors of autologous or allogeneic blood or marrow transplantation performed between 1974 and 2014 and identified the role of demographic and clinical factors associated with HPV-related squamous cell carcinomas using proportional subdistribution hazards model for competing risks. Standardized incidence ratio was used to compare the risk of HPV-related squamous cell carcinoma with age-, sex-, and calendar-specific incidence in the general population.
resultsThe median age at transplantation was 46 years (range = 0-78 years); 58.5% (n = 4642) were male, and 72.2% (n = 5727) were non-Hispanic White. Half (50.3%, n = 3991) of the patients had received an allogeneic blood or marrow transplantation. The standardized incidence ratio for oropharyngeal squamous cell carcinomas (n = 53) was 1.8 (95% confidence interval [CI] = 1.3 to 2.3) and for cervical squamous cell carcinoma among female blood or marrow transplantation recipients (n = 26) was 9.4 (95% CI = 6.3 to 13.6) compared with the general US population. The hazard of an HPV-related squamous cell carcinoma was higher among allogeneic blood or marrow transplantation recipients with chronic graft vs host disease (any HPV-related squamous cell carcinoma: HR = 6.24, 95% CI = 3.11 to 12.50; oropharyngeal: HR = 4.85, 95% CI = 2.11 to 11.15; cervical: HR = 4.98, 95% CI = 1.65 to 15.00; reference: autologous blood or marrow transplantation). Pre-blood or marrow transplantation radiation increased the risk of oropharyngeal squamous cell carcinoma (HR = 2.98, 95% CI = 1.57 to 5.65).
conclusionThese findings underscore the importance of risk-based HPV vaccination and surveillance after blood or marrow transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.